China widens Wegovy's weight-management licence to lower-BMI adults
China's regulator approved an updated Wegovy label covering adults with a BMI of 28 or more, or 24 to under 28 with at least one weight-related condition, matching Chinese obesity thresholds. The change is based on the 44-week STEP 12 trial in mainland China and Taiwan.
Source: Novo Nordisk China (press release, Chinese) (21 Oct 2026).